(Photo courtesy of Cerner)
Cerner on Thursday announced the completion of its purchase of Kantar Health for $375 million in cash – an acquisition it says will be a boost to its expanded efforts toward life sciences research capabilities.
WHY IT MATTERS
Kantar Health s analytics expertise spans a wide array of therapeutic areas: Alzheimer s, cancers, rare diseases and more. Its tools and policy expertise have been used by companies across the pharma and life sciences industries.
Cerner says combining those research and consulting bona fides with its own real-world data stores and portfolio of technologies can better help companies and research groups develop new therapeutics and improve health, wellness and treatment outcomes.
Cerner Corporation (NASDAQ:CERN) - Cerner Scoops Up Kantar Heath For $375M benzinga.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from benzinga.com Daily Mail and Mail on Sunday newspapers.
Get the latest industry news first when you subscribe to our daily newsletter.
We will never sell or share your information without your consent. See our privacy policy.
Cerner Announces Agreement to Acquire Health Division of Kantar
The acquisition will combine industry leading expertise and de-identified real-world data to advance clinical research development
December 16, 2020 Cerner Corporation announced an agreement to acquire Kantar Health, a division of Kantar Group, for $375 million in cash, subject to adjustment. Kantar Health is a leading data, analytics and real-world evidence and commercial research consultancy serving the life science industry. With this acquisition, Cerner plans to harness data to improve the safety, efficiency and efficacy of clinical research across life sciences, pharmaceuticals and health care at large. This acquisition is expected to allow Cerner’s
The two firms will work together to broaden the technology, tools, and resources available to hospitals and practices in less-accessible communities.
Cerner, a global health care technology firm, has announced investment in integrated research organization Elligo Health Research. Cerner will enter into a commercial agreement to expand data and tools available in its Cerner Learning Health Network to increase trial resources available to community and rural hospitals and practices; Cerner representatives also will join Elligo’s board.
John Potthoff, CEO of Elligo, told Outsourcing-Pharma that the alliance made sense, considering the similar aims of the two firms.
“
Given the overlap of our missions, we have known each other for a while now: Cerner for its access to practices and patients; Elligo for its ability to execute trials in healthcare,” he told us. “